Late Development
Webinar: The Latest in Sterile Product Development Strategies: Flexible Manufacturing & Integrated Delivery
Learn about the latest in sterile product development strategies from our expert. Join our webinar in November 2023.
Development of novel radiolabelling method - AAPS 2013
Development of novel radiolabelling method for low dose drug products for investigation of in Vivo performance in gamma scintigraphic studies.
Webinar: How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®
Learn about the Translational Pharmaceutics approach and hear insights from our team. Join our webinar in October 2023.
CPHI 2023 Seminar: How To Accelerate Drug Product Optimization: Integrated Program Delivery Using Translational Pharmaceutics®
During CPHI 2023, we will be hosting a seminar entitled, 'How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®'. There are limited spaces available. Register today.
Alternative Strategies for Development of Modified Release Dosage Forms
Modified-release (MR) formulations are in high demand. For formulators, they enable drugs to be released in the optimal gastrointestinal (GI) locations to achieve and maintain desirable plasma concentrations for extended periods, avoiding undesirable excursions outside the therapeutic range.
AAPS 2019 Poster - Clinical formulation development for poorly soluble 14C labelled molecules
Clinical studies involving the administration of 14C radio labelled drug substances provide critical information during development.The main application is the regulatory ADME study to assess the mass balance, routes and rates of elimination, and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.
Case Studies: Ensysce Biosciences
The First Kilograms of GMP Drug Substance
A core component of Quotient Sciences is our integrated capabilities in drug substance process research, development, and manufacturing. All are carried out at our state-of-the-art facility in Alnwick, UK.
Formulation Development
From preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.
Scientific Paper_Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery
Download our latest scientific publication entitled: Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery
Scientific Paper_ Development of a Prototype, Once-Daily, Modified Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
Download our latest scientific publication entitled: Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772”
Belmont Solubility Lunch Seminar with Nano PharmaSolutions
Join our complimentary co-hosted lunch seminar with Nano PharmaSolutions in Belmont, CA at Divino on May 18 to learn about how novel technologies and rapid clinical assessments can be utilized to achieve clinical success for poorly soluble molecules.
Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects
Quotient Sciences and Kadmon co-authored scientific publications on their recent NDA approved drug Belumosudil.
AAPS PharmSci 360 2023 | Orlando, FL
Quotient Sciences will be attending and exhibiting at AAPS PharmSci 360 2023 in Orlando from October 22-25.
Scientific Paper_Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
Download our latest scientific paper entitled: Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
Quotient Sciences ASCPT 2021 poster - A First in Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
Download our latest poster from the ASCPT 2021 conference, "A First in Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor"
Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations
Access our latest poster from AAPS 2021- Pharmaceutical and clinical performance comparisons of modified release multiparticulates and matrix tablet formulations. The purpose of this study is to review practical experiences of head to head pharmaceutical and clinical comparisons of MUPs and matrix tablet platforms to identify an optimal MR formulation.